CLIA Waiver Withdrawal Option Likely Will Be Explored By CDC Subcommittee
This article was originally published in The Gray Sheet
Executive Summary
The possibility of recommending a process whereby CLIA waivers can be withdrawn for certain in vitro diagnostic tests will be examined by a workgroup of CDC's Clinical Laboratory Improvement Advisory Committee